Long-term anticoagulation for venous thromboembolism: Duration of treatment and management of warfarin therapy

Clinics in Chest Medicine

Volumn 31, Issue 4, 2010, Pages 719-730

  Kearon, Clive ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Deep vein thrombosis; Duration of therapy; Pulmonary embolism; Treatment; Venous thromboembolism; Warfarin

Indexed keywords

D DIMER; PHOSPHOLIPID ANTIBODY; WARFARIN;

ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DRUG MONITORING; DRUG PREFERENCE; HUMAN; LONG TERM CARE; LUNG EMBOLISM; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; RISK FACTOR; SEX DIFFERENCE; THROMBOPHILIA; TREATMENT DURATION; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HUMANS; LONG-TERM CARE; RECURRENCE; RISK FACTORS; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 78049464217     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2010.06.003     Document Type: Review

References (102)

1. Hutten B.A., Prins M., Gent M., et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000, 18:3078-3083.
2. Merli G., Spiro T.E., Olsson C.G., et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001, 134:191-202.
3. Palareti G., Legnani C., Lee A., et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 2000, 84:805-810.
4. Piovella F., Crippa L., Barone M., et al. Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with recurrence and new thrombosis. Haematologica 2002, 87:515-522.
5. Prandoni P., Lensing A.W., Piccioli A., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002, 100:3484-3488.
6. Prandoni P., Lensing A.W., Cogo A., et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996, 125:1-7.
7. Heit J.A., Mohr D.N., Silverstein M.D., et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000, 160:761-768.
8. Palareti G., Legnani C., Cosmi B., et al. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost 2002, 87:7-12.
9. Prandoni P., Lensing A.W., Buller H.R., et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992, 327:1128-1133.
10. Kearon C., Kahn S.R., Agnelli G., et al. Antithrombotic therapy for venous thromboembolic disease. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133:454S-545S.
11. Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 1992, 340:873-876.
12. Levine M.N., Hirsh J., Gent M., et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995, 74:606-611.
13. Schulman S., Rhedin A.-S., Lindmarker P., et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995, 332:1661-1665.
14. Pini M., Aiello S., Manotti C., et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994, 72(2):191-197.
15. Pinede L., Ninet J., Duhaut P., et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 2001, 103:2453-2460.
16. Baglin T., Luddington R., Brown K., et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003, 362:523-526.
17. Ridker P.M., Goldhaber S.Z., Danielson E., et al. Long-term, low-intensity warfarin therapy for prevention of recurrent venous thromboembolism. N Engl J Med 2003, 348:1425-1434.
18. Spiezia L., Bernardi E., Tormene D., et al. Recurrent thromboembolism in fertile women with venous thrombosis: incidence and risk factors. Thromb Haemost 2003, 90:964-966.
19. Baglin T., Palmer C.R., Luddington R., et al. Unprovoked recurrent venous thrombosis: prediction by D-dimer and clinical risk factors. J Thromb Haemost 2008, 6:577-582.
20. Kearon C., Gent M., Hirsh J., et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999, 340:901-907.
21. Agnelli G., Prandoni P., Santamaria M.G., et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep vein thrombosis. N Engl J Med 2001, 345:165-169.
22. Agnelli G., Prandoni P., Becattini C., et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003, 139:19-25.
23. Kearon C., Ginsberg J.S., Kovacs M.J., et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003, 349:631-639.
24. Palareti G., Cosmi B., Legnani C., et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006, 355:1780-1789.
25. Farraj R.S. Anticoagulation period in idiopathic venous thromboembolism. How long is enough?. Saudi Med J 2004, 25:848-851.
26. Hansson P.O., Sorbo J., Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000, 160:769-774.
27. Murin S., Romano P.S., White R.H. Comparison of outcomes after hospitalization for deep vein thrombosis or pulmonary embolism. Thromb Haemost 2002, 88:407-414.
28. Schulman S., Wahlander K., Lundström T., et al. THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003, 349:1713-1721.
29. Douketis J.D., Kearon C., Bates S., et al. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998, 279:458-462.
30. Rodger M.A., Kahn S.R., Wells P.S., et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008, 179:417-426.
31. Kniffin W.D., Baron J.A., Barrett J., et al. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 1994, 154:861-866.
32. Schulman S., Lindmarker P., Holmstrom M., et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost 2006, 4:734-742.
33. Bell W.R., Simon T.L. Current status of pulmonary embolic disease: pathophysiology, diagnosis, prevention, and treatment. Am Heart J 1982, 103:239-261.
34. Stein P.D., Henry J.W. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 1995, 108:978-981.
35. Kearon C. Natural history of venous thromboembolism. Circulation 2003, 107:I22-I30.
36. Goldhaber S.Z., Visni L., De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999, 353:1386-1389.
37. Heit J.A., Silverstein M.D., Mohr D.N., et al. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999, 159:445-453.
38. Ribeiro A., Lindmarker P., Juhlin-Dannfelt A., et al. Echocardiography Doppler in pulmonary embolism: right ventricular dysfunction as a predictor of mortality rate. Am Heart J 1997, 134:479-487.
39. Naess I.A., Christiansen S.C., Romundstad P., et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007, 5:692-699.
40. Beyth R.J., Cohen A.M., Landefeld C.S. Long-term outcomes of deep-vein thrombosis. Arch Intern Med 1995, 155:1031-1037.
41. McRae S., Tran H., Schulman S., et al. Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet 2006, 368:371-378.
42. Lijfering W.M., Veeger N.J., Middeldorp S., et al. A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in thrombophilic families. Blood 2009, 114:2031-2036.
43. Segal J.B., Brotman D.J., Necochea A.J., et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. JAMA 2009, 301:2472-2485.
44. Palareti G., Legnani C., Cosmi B., et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 2003, 108:313-318.
45. Lindmarker P., Schulman S., Sten-Linder M., et al. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. Thromb Haemost 1999, 81:684-689.
46. Eichinger S., Pabinger I., Stumpflen A., et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 1997, 77(4):624-628.
47. Christiansen S.C., Cannegieter S.C., Koster T., et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 2005, 293:2352-2361.
48. Schulman S., Svenungsson E., Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 1998, 104:332-338.
49. Kearon C., Ginsberg J.S., Anderson D.R., et al. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost 2004, 2:743-749.
50. Prandoni P., Lensing A.W., Prins M.H., et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002, 137:955-960.
51. Siragusa S., Malato A., Anastasio R., et al. Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study. Blood 2008, 112:511-515.
52. Prandoni P., Prins M.H., Lensing A.W., et al. Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med 2009, 150:577-585.
53. Cosmi B., Legnani C., Cini M., et al. D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. Thromb Haemost 2005, 94:969-974.
54. Cosmi B., Legnani C., Tosetto A., et al. Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study. J Thromb Thrombolysis 2009, 28:381-388.
55. Eichinger S., Minar E., Bialonczyk C., et al. D-dimer levels and risk of recurrent venous thromboembolism. JAMA 2003, 290:1071-1074.
56. Shrivastava S., Ridker P.M., Glynn R.J., et al. D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost 2006, 4:1208-1214.
57. Poli D., Antonucci E., Ciuti G., et al. Combination of D-dimer, F1+2 and residual vein obstruction as predictors of VTE recurrence in patients with first VTE episode after OAT withdrawal. J Thromb Haemost 2008, 6:708-710.
58. Tait R.C., Lowe G.D., McColl M.D., et al. Predicting risk of recurrent venous thrombosis using a 5-point scoring system including fibrin D-dimer. J Thromb Haemost 2007, 5(Suppl 2):0-M-060.
59. Verhovsek M., Douketis J.D., Yi Q., et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med 2008, 149:481-490. W94.
60. Bruinstroop E., Klok F.A., Van De Ree M.A., et al. Elevated D-dimer levels predict recurrence in patients with idiopathic venous thromboembolism: a meta-analysis. J Thromb Haemost 2009, 7:611-618.
61. Decousus H., Leizorovicz A., Parent F., et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med 1998, 338:409-415.
62. PREPIC Study Group Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 2005, 112:416-422.
63. Kryle P., Minar E., Hirschl M., et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000, 343:457-462.
64. Kraaijenhagen R.A., in't Anker P.S., Koopman M.M., et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism [see comments]. Thromb Haemost 2000, 83:5-9.
65. Weltermann A., Eichinger S., Bialonczyk C., et al. The risk of recurrent venous thromboembolism among patients with high factor IX levels. J Thromb Haemost 2003, 1:28-32.
66. Eichinger S., Stumpflen A., Hirschl M., et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 1998, 80:566-569.
67. Den Heijer M., Willems H.P., Blom H.J., et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial. Blood 2007, 109:139-144.
68. Hron G., Kollars M., Binder B.R., et al. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 2006, 296:397-402.
69. van H.V., Christiansen S.C., Luddington R., et al. Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. Br J Haematol 2007, 138:769-774.
70. Besser M., Baglin C., Luddington R., et al. High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. J Thromb Haemost 2008, 6:1720-1725.
71. Hron G., Eichinger S., Weltermann A., et al. Prediction of recurrent venous thromboembolism by the activated partial thromboplastin time. J Thromb Haemost 2006, 4:752-756.
72. Hron G., Eichinger S., Weltermann A., et al. Family history for venous thromboembolism and the risk for recurrence. Am J Med 2006, 119:50-53.
73. Campbell I.A., Bentley D.P., Prescott R.J., et al. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. Br Med J 2007, 334:674-677.
74. Schulman S., Granqvist S., Holmström M., et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997, 336:393-398.
75. Ost D., Tepper J., Mihara H., et al. Duration of anticoagulation following venous thromboembolism: a meta-analysis. JAMA 2005, 294:706-715.
76. Kearon C. Indefinite anticoagulation after a first episode of unprovoked venous thromboembolism: yes. J Thromb Haemost 2007, 5:2330-2335.
77. Locadia M., Bossuyt P.M., Stalmeier P.F., et al. Treatment of venous thromboembolism with vitamin K antagonists: patients' health state valuations and treatment preferences. Thromb Haemost 2004, 92:1336-1341.
78. Palareti G., Leali N., Coccheri S., et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996, 348:423-428.
79. Beyth R.J., Quinn L.M., Landefeld S. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998, 105:91-99.
80. Kuijer P.M.M., Hutten B.A., Prins M.H., et al. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999, 159:457-460.
81. Beyth R.J., Quinn L., Landefeld C.S. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial. Ann Intern Med 2000, 133:687-695.
82. Dentali F., Douketis J.D., Lim W., et al. Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med 2007, 167:117-124.
83. Schulman S., Beyth R.J., Kearon C., et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133:257S-298S.
84. Gage B.F., Yan Y., Milligan P.E., et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006, 151:713-719.
85. Ruiz-Gimenez N., Suarez C., Gonzalez R., et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008, 100:26-31.
86. Palareti G., Cosmi B. Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients. Thromb Haemost 2009, 102:268-278.
87. Segal J.B., Streiff M.B., Hoffman L.V., et al. Management of venous thromboembolism: a systematic review for a practice guideline. Ann Intern Med 2007, 146:211-222.
88. Prandoni P., Noventa F., Ghirarduzzi A., et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007, 92:199-205.
89. Ansell J., Hirsh J., Hylek E., et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133:160S-198S.
90. Schulman S. Clinical practice. Care of patients receiving long-term anticoagulant therapy. N Engl J Med 2003, 349:675-683.
91. Garcia D.A., Witt D.M., Hylek E., et al. Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum. Ann Pharmacother 2008, 42:979-988.
92. Holbrook A.M., Pereira J.A., Labiris R., et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005, 165:1095-1106.
93. Garcia D., Regan S., Crowther M., et al. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest 2005, 127:2049-2056.
94. Crowther M.A., Ageno W., Garcia D., et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med 2009, 150:293-300.
95. Dentali F., Ageno W., Crowther M. Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost 2006, 4:1853-1863.
96. Dezee K.J., Shimeall W.T., Douglas K.M., et al. Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. Arch Intern Med 2006, 166:391-397.
97. Sconce E., Avery P., Wynne H., et al. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 2007, 109:2419-2423.
98. Rombouts E.K., Rosendaal F.R., Van Der Meer F.J. Daily vitamin K supplementation improves anticoagulant stability. J Thromb Haemost 2007, 5:2043-2048.
99. Heneghan C., Alonso-Coello P., Garcia-Alamino J.M., et al. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 2006, 367:404-411.
100. Poller L., Keown M., Ibrahim S., et al. An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage. J Thromb Haemost 2008, 6:935-943.
101. Kearon C., Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997, 336(21):1506-1511.
102. Douketis J.D., Berger P.B., Dunn A.S., et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133:299S-339S.